Welcome to the e-CCO Library!

DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or paediatrician refer a patient for suspected IBD?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. Atia1, G. Focht1, A. Assa2, B. Yerushalmi3, R. Shaoul4, D. S. Shouval5, A. Bar-Gil Shitrit6, B. Koslowsky6, I. Dotan7, R. Kariv8, E. Lavon8, D. Turner*1

Created: Friday, 22 February 2019, 9:41 AM
DOP31: Efficacy and safety of bone marrow-derived mesenchymal stem cells in refractory perianal fistulae in Crohn’s Disease: Results from a prospective monocentric study
Year: 2022
Source: ECCO'22
Authors: Reenaers Dr, C.(1);Vieujean , S.(1);Coimbra , C.(2);Gillard , R.(3);Meunier , P.(3);Boutaffala , L.(1);Louis , E.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP31: Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gerasimidis, K.(1)*;Nichols, B.(1);Briola, A.(1);Havlik, J.(2);Mascellani, A.(2);Milling, S.(3);Ijaz, U.(4);Quince, C.(5);Svolos, V.(1);Russell, R.K.(6);Hansen, R.(7);
Created: Friday, 14 July 2023, 10:43 AM
DOP31: Management and outcome of postoperative Crohn’s Disease in the elderly as compared to young adults: Data from Eneida registry
Year: 2021
Source: ECCO'21 Virtual
Authors: Mañosa Ciria, M.(1,2);Calafat, M.(1,2);Ricart, E.(2,3);Nos, P.(2,4);Iglesias, E.(5);Riestra, S.(6);López-Sanroman, A.(7);Vera, M.(8);Guardiola, J.(9);Hernández, V.(10);Rivero, M.(11);Carpio, D.(12);Mínguez, M.(13);Alba, C.(14);Martín-Arranz, M.D.(15);Rodríguez, E.(16);Gomollon, F.(17);Garcia-López, S.(18);Gutiérrez Casbas, A.(2,19,20);Calvet, X.(2,21);González-Muñoza, C.(22);Barrio, J.(23);P Gisbert, J.(2,24);Sicilia, B.(25);Pérez-Calle, J.L.(26);Bujanda, L.(2,27);Esteve, M.(2,28);Ramos, L.(29);Varela, P.(30);Sierra, M.(31);Merino, O.(32);Bermejo, F.(33,34);Barreiro-de Acosta, M.(35);Rodríguez, A.(36);Márquez, L.(37);Garcia-Bosch, O.(38);Cabriada, J.L.(39);Lorente, R.(40);Cañete, F.(1,2);Domènech, E.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP32 Clinical and molecular characterisation of patients with durable response to ustekinumab induction therapy: Results from the UNIFI phase 3 studies in moderate-to-severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Li, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J.R. Friednman

Created: Thursday, 30 January 2020, 10:12 AM
DOP32: Biologic treatment does not reduce the risk of postoperative peristomal pyoderma gangrenosum in Crohn’s Disease patients
Year: 2022
Source: ECCO'22
Authors: Iesalnieks, I.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP32: Crohn's disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lin, S.(1);Wang, J.(2);Mukherjee, P.(3);Mao, R.(1);West, G.(3);Czarnecki, D.(3);Zhao, S.(3);Elias, M.(3);Nguyen, Q.T.(3);Chandra, J.(3);Le, T.H.N.(3);Chen, M.H.(1);Dejanovic, D.(3);Holubar, S.(4);Olman, M.(3);Southern, B.(3);Hu, S.(5);Gordon, I.O.(5);Atabai, K.(6);Fiocchi, C.(3);Rieder, F.(7)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP32: Long-term outcomes of enterocutaneous fistula complicating Crohn’s Disease: The ECUFIT study from GETECCU
Year: 2021
Source: ECCO'21 Virtual
Authors: Rodríguez-Lago, I.(1);García Pérez, C.(2);Calafat, M.(3);Soto, M.P.(4);Calvo, M.(5);Sánchez Rodríguez, E.(6);Caballol, B.(7);Vela, M.(8);Rivero, M.(9);Muñoz, F.(10);De Castro, L.(11);Calvet, X.(12);García-Alonso, F.J.(13);Utrilla Fornals, A.(14);Ferreiro-Iglesias, R.(15);González-Muñoza, C.(16);Chaparro, M.(17);Luis, B.(18);Sicilia, B.(19);Alfambra, E.(20);Rodriguez, A.(21);Pérez Fernández, R.(22);Rodríguez, C.(23);Almela, P.(24);Argüelles, F.(25);Busquets, D.(26);Tamarit-Sebastián, S.(27);Reygosa Castro, C.(28);Jiménez, L.(29);Marín-Jiménez, I.(30);Alcaide, N.(31);Fernández-Salgado, E.(32);Iglesias Gómez, Á.(33);Ponferrada, Á.(34);Pajares, R.(35);Roncero, Ó.(36);Morales-Alvarado, V.J.(37);Cabriada, J.L.(1);Domènech, E.(3);Barreiro-de Acosta, M.(15)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Hisamatsu*1, S. Kato2, R. Kunisaki3, M. Matsuura4, M. Nagahori5, S. Motoya6, M. Esaki7, N. Fukata8, S. Inoue9, T. Sugaya10, H. Sakuraba11, F. Hirai12, K. Watanabe13,14, T. Kanai15, M. Naganuma15, H. Nakase16, Y. Suzuki17, M. Watanabe5, T. Hibi18, M. Nojima19, T. Matsumoto20, DIAMOND2 Study Group1

Created: Friday, 22 February 2019, 9:41 AM
DOP33 Stratification of patients for treatment with adalimumab by a combination of immune-profiling and in vivo efficacy studies in a novel mouse model of ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Gropp1, H. Jodeleit1, J. Caesar1, C. Villarroel Aguilera1, S. Sterz2, L. Holdt2, F. Beigel3, S. Breiteneicher3, J. Stallhofer3, M. Siebeck1

Created: Thursday, 30 January 2020, 10:12 AM
DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s disease : a multi-centre Belgian cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Liefferinckx*1, B. Verstockt2, A. Gils3, M. Noman2, C. Van Kemseke4, E. Macken5, M. De Vos6, W. Van Moerkercke7, J-F. Rahier8, P. Bossuyt9, J. Dutré10, E. Humblet11, D. Staessen12, H. Peters13, P. Van Hootegem14, E. Louis4, D. Franchimont1, F. Baert15, S. Vermeire2

Created: Friday, 22 February 2019, 9:41 AM
DOP33: Predictors of ileo-rectal anastomosis, permanent ileostomy and recurrence of disease after total colectomy for Crohn’s Colitis: Results over 20 years
Year: 2021
Source: ECCO'21 Virtual
Authors: Rottoli, M.(1);Melina, M.(1);Tanzanu, M.(1);Romano, A.(1);Belvedere, A.(1);Parlanti, D.(1);Pezzuto, A.P.(1);Salice, M.(2);Rizzello, F.(2);Gionchetti, P.(2);Poggioli, G.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP33: Role of adherent and invasive E. coli in Crohn’s Disease: Lessons from the postoperative recurrence model
Year: 2022
Source: ECCO'22
Authors: Buisson, A.(1);Sokol, H.(2);Hammoudi, N.(3);Nancey, S.(4);Treton, X.(5);Nachury, M.(6);Fumery, M.(7);Hébuterne, X.(8);Rodrigues, M.(9);Hugot, J.P.(10);Boschetti, G.(4);Stefanescu, C.(5);Wils , P.(6);Seksik, P.(2);Le Bourhis, L.(3);Bezault, M.(11);Sauvanet, P.(9);Pereira, B.(12);Allez, M.(3);Barnich, N.(9);
Created: Friday, 11 February 2022, 3:52 PM
DOP33: Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn's disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ke, B.J.(1);Abdurahiman, S.(1);Biscu, F.(1);Verstockt, S.(1);Verstockt, B.(2);de Hertogh, G.(3);Vermeire, S.(2);Matteoli, G.(1)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP34 Transplantation of human intestine into the mouse: A novel platform for study of inflammatory enterocutaneous fistulas
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R.S. Bruckner1, E. Nissim-Eliraz2, N. Marsiano2, E. Nir2, H. Shemesh2, M. Leutenegger1, C. Gottier1, S. Lang1, M.R. Spalinger1, S. Leibl3, G. Rogler1,4, S. Yagel5, M. Scharl1,4, N.Y. Shpigel2

Created: Thursday, 30 January 2020, 10:12 AM
DOP34: Comparison of the risk of clinical recurrence after ileocolonic resection for Crohn's Disease for modified Rutgeerts' score i2a and i2b categories: Individual patient data meta-analysis
Year: 2022
Source: ECCO'22
Authors: Riviere, P.(1);Pekow, J.(2);Hammoudi, N.(3);Wils, P.(4);De Cruz, P.(5);Wang, C.(6);Mañosa, M.(7);Ollech, J.(2);Allez, M.(3);Nachury, M.(4);Kamm, M.(5);Maya, A.(2);Ferrante, M.(8);Buisson, A.(9);Singh, S.(10);Laharie, D.(1);Momar, D.(11);Fumery, M.(12);
Created: Friday, 11 February 2022, 3:52 PM
DOP34: Disease activity patterns during the first 5 years after diagnosis in children with ulcerative colitis: a population-based study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Aloi*1, M. Bramuzzo2, L. Norsa3, S. Arrigo4, M. Distante5, E. Miele6, A. Agrusti2, C. Romano7, C. Giobbi5, R. Panceri8, L. D’Antiga3, S. Cucchiara5, P. Alvisi9, SIGENP IBD Working Group1

Created: Friday, 22 February 2019, 9:41 AM
DOP34: Human MD2 deficiency - an inborn error of immunity predisposing to early onset Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Li, Y.(1)*;Yu, Z.(1);Schenk, M.(1);Lagovsky, I.(2);Illig, D.(1);Walz, C.(3);Rohlfs, M.(1);Conca, R.(1);Muise, A.(4);Snapper, S.(5);Uhlig, H.(6);Garty, B.(7);Klein, C.(1);Kotlarz, D.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP34: Long-term outcome of Acute Severe Ulcerative Colitis responsive to intravenous steroid: A multicenter study of the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)
Year: 2021
Source: ECCO'21 Virtual
Authors: Festa, S.(1);Scribano, M.L.(2);Aratari, A.(1);Bezzio, C.(3);Principi, M.(4);Pugliese, D.(5);Ribaldone, D.G.(6);Furfaro, F.(7);Mocci, G.(8);Spagnuolo, R.(9);Vernia, P.(10);Costa, F.(11);Cosintino , R.(2);De Biasio, F.(1);Saibeni, S.(3);Armuzzi, A.(5);Papi, C.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP35 Monitoring of mucosal T cells subsets under biotherapies in IBD: responders exhibit a phenotype similar to healthy controls
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Hammoudi1, K. Perez1, D. Hassid1, M.L. Tran Minh1, J.M. Gornet1, C. Baudry1, N. Lourenco1, B. Gergaud2, V. Chardiny2, J. Bonnet1, L. Le Bourhis2, M. Allez1

Created: Thursday, 30 January 2020, 10:12 AM